Ipsen SA

Common Name

Ipsen

Country

France

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

5,358

Ticker

IPN

Exchange

EURONEXT

Website

www.ipsen.com

Description

Ipsen S.A. is a global biopharmaceutical company specializing in the discovery, development, and commercialization of innovative medicines. The firm's primary focus is on specialty care, targeting thr... Show more

Income Statement Balance Sheet Group Entities

Ipsen's Financial Statements Preview

Below are the financial statements of Ipsen, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?

Learn More

All figures in millions of EUR	2024 as of 2024-12-31	2023 as of 2023-12-31
Assets	—	—
Goodwill	699.5^a	663.9^a
Other intangible assets	2,518.3^a	2,678.8^a
Property, plant & equipment	664.2^a	574.6^a
Equity investments	157.9^a	114.7^a
Investments in equity-accounted companies	17.3^a	16.7^a
Non-current financial assets	0.2^a	0.3^a
Deferred tax assets	284.7^a	324.8^a
Other non-current assets	75.7^a	50.8^a
Total non-current assets	4,417.8^a	4,424.5^a
Inventories	285.5^a	289.5^a
Trade receivables	697.2^a	631.3^a
Current tax assets	58.9^a	106.2^a
Current financial assets	8.5^a	10.6^a
Other current assets	293.1^a	332.3^a
Cash and cash equivalents	678.1^a	528.4^a
Total current assets	2,021.2^a	1,898.4^a
Total assets	6,439^a	6,322.9^a
Equity and liabilities	—	—
Share capital	83.8^a	83.8^a
Additional paid-in capital and consolidated reserves	3,616.2^a	3,100.8^a
Net profit/(loss) for the period	345.9^a	644.4^a
Foreign exchange differences	135.8^a	-3.9^a
Equity attributable to Ipsen S.A. shareholders	4,181.6^a	3,825.1^a
Equity attributable to non-controlling interests	0.2^a	-1.3^a
Total shareholders' equity	4,181.8^a	3,823.9^a
Retirement benefit obligation	24.2^a	24.4^a
Non-current provisions	35.7^a	32.8^a
Non-current financial liabilities	392.8^a	341.4^a
Deferred tax liabilities	55.2^a	226.4^a
Other non-current liabilities	243.8^a	247.2^a
Total non-current liabilities	751.7^a	872.2^a
Current provisions	47.5^a	56.8^a
Current financial liabilities	149.8^a	125.1^a
Trade payables	854.8^a	771.4^a
Current tax liabilities	24.9^a	41.4^a
Other current liabilities	427.9^a	623.2^a
Bank overdrafts	0.6^a	9^a
Total current liabilities	1,505.4^a	1,626.8^a
Total equity & liabilities	6,439^a	6,322.9^a

Download Data

Verified Sources Behind Ipsen’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Ipsen’s data sources below and access millions more through our Disclosure Search.

a. Ipsen's Universal Registration Document (URD) 2024

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Ipsen SA

Ipsen's Financial Statements Preview

Verified Sources Behind Ipsen’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

Swedish Orphan Biovitrum AB (publ)

Alkem Laboratories Ltd

Glenmark Pharmaceuticals Ltd

Richter Gedeon Vegyeszeti Gyar Nyrt

H Lundbeck A/S

Zydus Lifesciences Ltd